The World of Health & Medicine News

Investors managing $11.5 trillion urge food companies to diversify away from animal proteins

Investors managing $11.5 trillion urge food companies to diversify away from animal proteins

 Investors managing $11.5 trillion in assets are calling on major food companies and retailers to diversify into more plant-based protein sources to enhance supply chain resiliency and mitigate food security risks.

As global interest rates and prolonged higher temperatures help lift feed costs, and with prices for products such as eggs susceptible to unpredictable bird flu outbreaks, food companies are facing increasingly brittle animal supply chains and risk investor divestment should their exposure be deemed too high.

A group of 73 investors engaging in the Farm Animal Investment Risk and Return Initiative investor network are calling on manufacturers and retailers to seize the “growth and health” opportunities alternative protein sources present, according to a FAIRR report set for publication on Tuesday.

Through FAIRR, the investors have engaged with 20 companies, including manufacturers Nestle, Danone and Kraft Heinz and retailers Amazon, Carrefour and Walmart.

“For food and retail, protein diversification is a key element to reduce your CO2 emissions,” Sophie Kamphuis, senior advisor for responsible investment at Dutch asset manager MN, told Reuters.

“We like it if companies set sales targets and launch products, but we also want that to be replacing animal proteins,” Kamphuis added, naming Ahold Delhaize’s (AD.AS), opens new tab target for its European retailers – committing to 50% of proteins sold being plant-based by 2030 – as a good example.

Private investment in non-meat protein sources, such as beans, pulses, plant-based alternatives to animal products and novel methods like cell cultivation, fell to just over $1 billion last year, from a spike of almost $7 billion in 2021, according to The Good Food Institute.

When it comes to protein diversification that focuses on meat substitutes, the recurring problem has been that the products are just not good enough, Jo Raven, director of thematic research and corporate innovation at FAIRR, told Reuters.

“The reality is they did not get the taste and texture right, and consumers are fickle creatures,” Raven said. “So if they purchase it once and just didn’t like it, they’re going to be a harder group to convince otherwise.”

spot_img

Explore more

spot_img

WHO says mpox now detected in more countries, with 17 deaths...

WHO says mpox now detected in more countries, with 17 deaths in Africa over six weeks The World Health Organization (WHO) said on Friday that...

Metsera the US obesity biotech at centre of Novo, Pfizer bidding...

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is...

Eli Lilly says weight-loss pill a candidate for speedy approval under...

Eli Lilly says weight-loss pill a candidate for speedy approval under new US programme Eli Lilly said its experimental weight-loss pill met most criteria for...

BridgeBio surges as muscle disorder drug scores ‘best case’ trial win

BridgeBio surges as muscle disorder drug scores 'best case' trial win BridgeBio Pharma (BBIO.O), opens new tab said on Monday its experimental drug for a rare muscle...

US FDA warns four firms over unapproved fluoride drugs for children

US FDA warns four firms over unapproved fluoride drugs for children The U.S. Food and Drug Administration said on Friday it warned four companies that...

Inhibrx shares surge after bone cancer drug slows disease progression in...

Inhibrx shares surge after bone cancer drug slows disease progression in trial Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of...

Lilly partners with Nvidia on AI supercomputer to speed up drug...

Lilly partners with Nvidia on AI supercomputer to speed up drug development  Eli Lilly (LLY.N), opens new tab said on Tuesday it was collaborating with Nvidia (NVDA.O), opens...

China’s Innovent says its GLP-1 works better than Novo’s semaglutide in...

China’s Innovent says its GLP-1 works better than Novo’s semaglutide in diabetes study  China’s Innovent Biologics said on Monday its GLP-1 injection led to more...